TAMRA PERDUE: Open Payments
NPI 1316912405 · LYNCHBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,161 in 100 payments from 19 companies in 2025. Trend: 2023 $1,007 · 2024 $890 · 2025 $2,161
Food & beverage: $2,161
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 21 | $577 |
| ABBVIE INC. | 32 | $480 |
| Regeneron Healthcare Solutions, Inc. | 9 | $321 |
| Madrigal Pharmaceuticals | 4 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $123 |
| Gilead Sciences, Inc. | 3 | $85 |
| Phathom Pharmaceuticals, Inc. | 6 | $84 |
| QOL Medical, LLC | 3 | $66 |
| Ipsen Biopharmaceuticals, Inc | 3 | $53 |
| PFIZER INC. | 2 | $38 |
Products named: TREMFYA, RINVOQ, DUPIXENT, REZDIFFRA, ENTYVIO, LINZESS, VOQUEZNA, Sucraid.
Industry payments across VA — which companies pay providers there.
